Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ASTX727 for the Treatment of IDH Mutant Recurrent Glioma

Trial Status: temporarily closed to accrual

This phase I trial studies the side effects and best dose of ASTX727 in treating patients with IDH mutant glioma that has come back (recurrent). ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine may slow down how fast decitabine is broken down by the body. Decitabine may block abnormal cells or tumor cells from growing. This study aims to find the highest dose of ASTX727 that can be administered safely.